Intangible Assets, Net (Tables)

12 Months Ended

Dec. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets

The gross carrying amounts and net book value of our intangible assets are as follows:

		December 31, 2019
	Useful Life (In Years)	Gross Carrying Amount		Accumulated Amortization			Accumulated Impairment Charges		Net Book Value
Ryanodex intangible	20	$	15,000	$	(2,454	)	$	—	$	12,546
Developed technology	5	8,100		(5,063		)	—		3,037
Total		$	23,100	$	(7,517	)	$	—	$	15,583

		December 31, 2018
	Useful Life (In Years)	Gross Carrying Amount		Accumulated Amortization			Accumulated Impairment Charge			Net Book Value
Docetaxel product rights	10	$	11,220	$	(1,281	)	$	(9,939	)	$	—
Ryanodex intangible	20	15,000		(1,554		)	—			13,446
Developed technology	5	8,100		(3,443		)	—			4,657
Total		$	34,320	$	(6,278	)	$	(9,939	)	$	18,103

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

Based on definite-lived intangible assets recorded as of December 31, 2019, and assuming that the underlying assets will not be impaired and that the Company will not change the expected lives of the assets, future amortization expenses are estimated as follows:

	Estimated Amortization Expense
Year Ending December 31,
2020	$	2,666
2021	2,623
2022	1,369
2023	1,570
2024	1,570
All other	5,785
Total estimated amortization expense	$	15,583